Bard Associates’s AYTU BioPharma AYTU Stock Holding History

Bard Associates’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8	Closed	-$71K	–	178
2017 Q4	$71K	Buy	+8	New	+$95.5K	0.03%	162

Other funds holding AYTU

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bard Associates's AYTU Position: Q1 2018 in Review

Bard Associates sold out of AYTU BioPharma (AYTU) in Q1 2018, closing a stake of 8 shares — an estimated $71K sold.

Bard Associates first reported a position in AYTU in Q4 2017 and held it in 1 quarter. The position peaked at $71K in Q4 2017. 10 funds tracked by Wall St. Rank hold AYTU as of Q1 2018.

Bard Associates reported no remaining AYTU BioPharma position as of Q1 2018 after selling out during the quarter.
Bard Associates sold 8 AYTU BioPharma shares in Q1 2018, an estimated $71K.
Bard Associates first reported a position in AYTU BioPharma in Q4 2017 and held it in 1 quarter.
Bard Associates's AYTU BioPharma position peaked at $71K in Q4 2017.
10 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2018.

Based on Bard Associates's 13F filing for Q1 2018, filed 14 May 2018.